北陆药业：拟向特定对象增发募资不超过3亿元

Group 1 - North Lu Pharmaceutical announced a stock issuance plan approved by the 2024 annual general meeting, aiming to raise no more than 300 million yuan [1] - The stock issuance will target no more than 35 specific investors, with the issuance price set at no less than 80% of the average trading price over the previous 20 trading days [1] - The raised funds will be allocated to three main projects: approximately 234 million yuan for the construction of a pharmaceutical production workshop and smart warehouse, 39.86 million yuan for the renovation of a new production line for iodine-based raw materials, and 26.4 million yuan for working capital [1] Group 2 - As of the latest report, North Lu Pharmaceutical has a market capitalization of 4.9 billion yuan [2] - The company's revenue composition for 2024 indicates that 98.88% of its income will come from pharmaceutical production, while other business revenues will account for 1.12% [1]